miRNAs as potential game-changers in renal cell carcinoma: Future clinical and medicinal uses

miRNAs as potential game-changers in renal cell carcinoma: Future clinical and medicinal uses

Renal cell carcinoma (RCC) has the highest mortality rate of all genitourinary cancers, and its prevalence has grown over time. While RCC can be surgically treated and recurrence is only probable in a tiny proportion of patients, early diagnosis is crucial. Mutations in a large number of oncogenes a...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice Vol. 245; p. 154439
Main Authors: Elballal, Mohammed S., Sallam, Al-Aliaa M., Elesawy, Ahmed E., Shahin, Reem K., Midan, Heba M., Elrebehy, Mahmoud A., Elazazy, Ola, El-Boghdady, Rawnaa Mohammed, Blasy, Shaimaa Hassan, Amer, Nada Mahmoud, Farid, Hadeer Ibrahim, Mohammed, Dina Ashraf, Ahmed, Shaymaa Adly, Mohamed, Sally Samir, Doghish, Ahmed S.
Format: Journal Article
Language:English
Published: Germany Elsevier GmbH 01-05-2023
Subjects:
Biomarkers, Tumor - metabolism
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - metabolism
Carcinoma, Renal Cell - therapy
Drug resistance
Gene Expression Regulation, Neoplastic
Humans
Kidney Neoplasms - genetics
Kidney Neoplasms - metabolism
Kidney Neoplasms - therapy
MicroRNAs - metabolism
MiRNA
Oncogenes
P53
Renal cell carcinoma
VEGF
RAS
SERPINE1
PTEN
FOXM1
Drug resistance
ETS1
NF-κB
PI3K
OCT2
mTOR
REGγ
MDR
JAK2
PSA
DAPK
MiRNA
TET1
TSC1
MAPK
DKK1
MMP
ZEB2
RCC
ARIDIA
DMTF1
ARF
MET
SIRT
MEG3
miRNAs
HO-1
Renal cell carcinoma
TGF-β
Wnt
PAK5
ATF-2
OS
VEGF
STAT3
NAP1L1
Akt
MLH1
P53
KLF6
ccRCC
HER
PDCD4
KRAS
MTA-1
Caki-1-SR
EZH2
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal cell carcinoma (RCC) has the highest mortality rate of all genitourinary cancers, and its prevalence has grown over time. While RCC can be surgically treated and recurrence is only probable in a tiny proportion of patients, early diagnosis is crucial. Mutations in a large number of oncogenes and tumor suppressor genes contribute to pathway dysregulation in RCC. MicroRNAs (miRNAs) have considerable promise as biomarkers for detecting cancer due to their special combination of properties. Several miRNAs have been proposed as a diagnostic or monitoring tool for RCC based on their presence in the blood or urine. Moreover, the expression profile of particular miRNAs has been associated with the response to chemotherapy, immunotherapy, or targeted therapeutic options like sunitinib. The goal of this review is to go over the development, spread, and evolution of RCC. Also, we emphasize the outcomes of studies that examined the use of miRNAs in RCC patients as biomarkers, therapeutic targets, or modulators of responsiveness to treatment modalities.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2023.154439